Founded in San Francisco, Nurix Therapeutics is dedicated to developing novel drugs that harness the body's natural processes to treat cancer and inflammatory diseases. The company focuses on targeted protein degradation, using its proprietary DELigase platform to create small molecule drugs that either activate or inhibit the natural process of protein degradation. Nurix aims to address unmet medical needs and empower the body to fight diseases more effectively.
Nurix has attracted notable investors and industry leaders, contributing to its rapid advancements in the field of targeted protein degradation. The company has achieved significant milestones, including the development of a robust pipeline of innovative medicines targeting various forms of cancer and inflammatory conditions. Nurix's impact is evident in its pioneering approach to drug discovery, positioning it at the forefront of a new modality in disease treatment.
